Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir, 2025, Mafi et al

Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir

John N. Mafi, Sitaram Vangala, Moira K. Kapral, Peter E. Wu, Manying Cui, Artem Romanov, Katherine L. Kahn

Abstract
Randomized clinical trials of nirmatrelvir-ritonavir found reduced COVID-19–related hospitalizations among unvaccinated patients but not vaccinated patients. Although advanced age is the strongest predictor of severe COVID-19, the median ages of the trial participants were 42 and 46 years. It remains unknown whether the results of these trials generalize to older and highly vaccinated populations. We made use of a natural experiment to compare hospitalization and mortality outcomes in vaccinated older adults with vs without restricted access to nirmatrelvir-ritonavir.

Link (JAMA) [Paywall]

 

Science: 'Paxlovid: You'd Have Expected More'